Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
- None.
- None.
Insights
The acquisition of PKU GOLIKE® by Eton Pharmaceuticals represents a strategic expansion of the company's metabolic franchise. The transaction's expected accretion to 2024 earnings and the estimated peak sales exceeding $10 million annually are significant figures for a niche market. The U.S. phenylketonuria (PKU) medical formula market's estimated $100 million annual value indicates a substantial opportunity for revenue growth, especially considering the limited patient population of 8,000 PKU patients utilizing medical formulas. The inclusion of rights to future line extensions and a first negotiation right for an innovative drug candidate (RLF-OD032) under development for PKU treatment may further enhance Eton's market position in the coming years.
From a financial perspective, the accretive nature of the deal suggests that Eton's EPS (earnings per share) is expected to increase post-acquisition. Investors will likely monitor the integration process and the effectiveness of Eton's sales force in increasing PKU GOLIKE's market penetration. The financial success of this acquisition will depend on how well Eton can leverage its existing relationships in the metabolic community and how insurance coverage policies evolve for PKU medical formulas.
Understanding the PKU medical formula market dynamics is important for assessing the potential impact of Eton's acquisition. PKU GOLIKE's proprietary Physiomimic™ technology and its taste-masked, odor-free coating are designed to improve patient compliance and experience. These product differentiators could provide a competitive advantage in the market. However, the actual impact on market share will depend on the effectiveness of Eton's marketing strategies and the ability to educate both healthcare professionals and patients on the benefits of PKU GOLIKE® over existing alternatives.
Moreover, the successful commercialization of PKU GOLIKE in Europe since 2019 by Relief's subsidiary APR suggests a tested and viable product. Eton's challenge will be to replicate this success in the U.S. market, which may have different regulatory and competitive landscapes. The market research will need to closely follow patient and healthcare professional feedback, as well as sales performance data, to gauge the adoption rate and to refine targeting strategies for the metabolic sales force.
The medical implications of this acquisition extend beyond the financials. PKU is a rare metabolic disorder requiring lifelong management and the availability of improved medical formulas like PKU GOLIKE® can significantly affect patient quality of life. The delayed amino acid release formulation of the product aligns with the dietary management needs of PKU patients, potentially offering better satiety and metabolic control. The long-term health outcomes and the potential reduction in healthcare costs associated with better-managed PKU could be a point of interest for medical research and health economics.
Furthermore, the ongoing development of line extensions for other metabolic conditions and the new drug candidate RLF-OD032 suggest a commitment to innovation in the rare disease space. The expected FDA filing of RLF-OD032 as a 505(b)(2) New Drug Application indicates a potentially expedited regulatory pathway, leveraging previous research data. The medical community will be watching closely for clinical trial results and FDA feedback, which will have implications for the standard of care in PKU treatment.
- PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point
- Transaction is expected to be accretive to 2024 earnings
- Estimated peak sales of more than
$10 million annually - U.S. phenylketonuria ("PKU") medical formula market estimated to be
$100 million annually
DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. rights to PKU GOLIKE® from RELIEF THERAPEUTICS Holding SA (“Relief”) (SIX: RLF, OTCQB: RLFTF, RLFTY).
“We are excited to be partnering with Relief on PKU GOLIKE in the United States. After extensive discussions with metabolic geneticists, dieticians, and PKU patients, we believe PKU GOLIKE is the best product in the estimated
“We are very pleased to gain this partnership with Eton for PKU GOLIKE patients in the US as it is aligned with RELIEF’s strategy to enhance patient access to our innovative products,” said Michelle Lock, interim CEO of Relief. “Eton brings valuable know-how in the metabolic space as well as commercialization expertise for products in rare diseases.”
PKU is a rare inherited disorder caused by a defect in the enzyme needed to break down phenylalanine, leading to a toxic buildup of phenylalanine when eating foods that contain proteins. Treatment of PKU requires patients to follow a strict diet that severely limits phenylalanine content and typically requires low protein foods supplemented by phenylalanine-free medical formulas. Excessive levels of phenylalanine in the blood accumulate in the brain and inhibit proper brain development. It is estimated that 8,000 PKU patients in the U.S. utilize medical formulas to manage their diet.
PKU GOLIKE® is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of PKU under medical supervision. PKU GOLIKE’s taste-masked, odor-free coating technology is designed to provide a better taste and a superior experience compared to alternative PKU medical formulas. In addition, PKU GOLIKE’s delayed amino acid release formulation is designed to keep patients full for a longer period of time. Relief launched PKU GOLIKE Granules in the United States in the fourth quarter of 2022 and the PKU GOLIKE Tropical Bar in the second quarter of 2023. Only a few months into the product’s launch, PKU GOLIKE’s fourth quarter net sales in the U.S. were at an annual run rate of more than
Eton plans to promote PKU GOLIKE with its existing metabolic sales force, which currently promotes Eton’s Carglumic Acid, Betaine, and Nitisinone products. PKU patients’ care is typically overseen by metabolic geneticists and their support staff of nurse practitioners and registered dieticians. Medical formulas for PKU are frequently covered by insurance and are regulated by the FDA as medical food products. PKU GOLIKE is exclusively distributed in the United States by Pentec Health. Patients and healthcare professionals seeking additional information on the product can visit www.PKUGOLIKE.com.
The transaction is expected to be accretive to Eton’s 2024 earnings and the company expects peak sales of more than
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
About RELIEF THERAPEUTICS Holding SA
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief’s portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented Physiomimic™ and TEHCLO™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Relief’s mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Monza, Italy. Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
About Phenylketonuria (PKU)
Phenylketonuria (PKU) is caused by a defect of the enzyme needed to break down phenylalanine (Phe), leading to a toxic buildup of Phe from the consumption of foods containing protein or aspartame. Untreated PKU can result in global developmental delay or severe irreversible intellectual disability, as well as growth failure, hypopigmentation, motor deficits, ataxia and seizures. Living with PKU requires a limited diet and very careful management. If left unmanaged, PKU can lead to devastating consequences, such as brain damage. People living with PKU do not have the ability to metabolize Phe, which is found in many foods, and they require supplementation of amino acid-based phenylalanine-free medical formulas as part of an effort to prevent protein deficiency and optimize metabolic control. Medical formulas used in PKU are challenged to provide a range of amino acids slowly and without a medicinal aftertaste.
About PKU GOLIKE
PKU GOLIKE® products are foods for special medical purposes (FSMPs) for the dietary management of PKU in both children and adults for use under medical supervision. Developed with Relief’s proprietary, patent-protected Physiomimic Technology™ drug delivery platform, PKU GOLIKE® products are the first prolonged-release amino acid FSMPs, characterized by a special coating that ensures physiological absorption of the amino acids mirroring that of natural proteins. The special coating also masks the unpleasant taste, odor and aftertaste of the amino acids. PKU GOLIKE® granules are flavorless and can be mixed with many foods. PKU GOLIKE® products contain all 19 amino acids that people with PKU need to maintain neurological and muscular health and is fortified with 27 essential vitamins and minerals, including ones normally found in protein-rich foods like iron, calcium and vitamin B12. The PKU GOLIKE® line of products are available in convenient packets (PKU GOLIKE Plus® 3-16 and 16+) and medical formula bars (PKU GOLIKE BAR®). PKU GOLIKE® products have been commercially available in the U.S. since October 2022. For more information, visit www.pkugolike.com (Please note this site is intended for U.S. audiences only).
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
What did Eton Pharmaceuticals acquire from Relief Therapeutics?
What is the estimated annual market size for PKU medical formulas in the U.S.?
What is the expected impact of the transaction on Eton's earnings in 2024?
What is the estimated peak sales for PKU GOLIKE® annually?
What is the unique feature of PKU GOLIKE® medical formula product?
